{
    "clinical_study": {
        "@rank": "112773", 
        "arm_group": [
            {
                "arm_group_label": "Vapendavir 300 mg tablet", 
                "arm_group_type": "Experimental", 
                "description": "Vapendavir 300 mg tablet single dose with up to 7 day washout period followed by two vapendavir 132 mg capsules single dose"
            }, 
            {
                "arm_group_label": "Two Vapendavir 132 mg capsules", 
                "arm_group_type": "Experimental", 
                "description": "Two Vapendavir 132 mg capsules single dose with up to 7 day washout period followed by Vapendavir 300 mg tablet single dose"
            }
        ], 
        "brief_summary": {
            "textblock": "This Phase 1 study aims to determine the oral bioavailability of a single dose of a new\n      vapendavir tablet formulation and compare it to that of the previous vapendavir capsule\n      formulation.  The safety of both drug products will also be assessed."
        }, 
        "brief_title": "A Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Formulations in Healthy Volunteers", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must be male or female between 18 and 55 years of age (inclusive) with BMI between 18\n             and 30 kg/m2 (inclusive), and weight \u226550 kg at the time of screening\n\n          -  Capable of giving written informed consent\n\n          -  Subject is able to understand and comply with the protocol requirements, instructions\n             and restrictions\n\n          -  Healthy on the basis of physical examination, medical history, medication usage, VS,\n             ECGs, and clinical laboratory tests\n\n          -  Female subjects must be of non-childbearing potential\n\n          -  Male subjects must agree to use a double barrier method of birth control\n\n        Exclusion Criteria:\n\n          -  Positive results for Hepatitis B, Hepatitis C, or HIV\n\n          -  Frequent use of tobacco products, including cigarettes, cigars, chewing tobacco\n\n          -  A medical history of significant hematological, gastrointestinal, respiratory, renal,\n             hepatic, cerebrovascular, immunologic, psychiatric or cardiovascular disease or\n             event; Current or recent respiratory infection\n\n          -  Presence or history of significant allergy\n\n          -  Clinically significant abnormalities noted on ECG\n\n          -  Screening vital signs representing sustained elevated blood pressure\n\n          -  Presence of significant gastrointestinal abnormalities\n\n          -  Safety laboratory abnormalities noted at screening which are clinically significant\n\n          -  Current or defined history of abuse of alcohol or illicit drugs\n\n          -  A positive pregnancy test at screening\n\n          -  Poor vein access or fear of venipuncture or sight of blood"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101866", 
            "org_study_id": "BTA798-103"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vapendavir 300 mg tablet", 
                "description": "tablet - single dose", 
                "intervention_name": "Vapendavir 300 mg tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Two Vapendavir 132 mg capsules", 
                "description": "2 capsules - single dose", 
                "intervention_name": "Vapendavir 132 mg capsules", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Bioavailability Study", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Paul", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55101"
                }, 
                "name": "Investigative Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Single-Center, Open-Label, Two-Period, Two-Sequence, Crossover, Comparative Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Product Formulations in Healthy Volunteers", 
        "overall_contact": {
            "email": "mmatson@prismresearchinc.com", 
            "last_name": "Mark Matson, M.D.", 
            "phone": "651 641 2900"
        }, 
        "overall_official": {
            "affiliation": "Prism Research, Inc", 
            "last_name": "Mark Matson, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PK and statatistical analyses will be performed to determine the Primary Outcome Measure", 
            "measure": "Systemic exposure profile of a single dose of a vapendavir 300 mg tablet compared to the exposure profile following a single dose of two 132 mg vapendavir capsules", 
            "safety_issue": "No", 
            "time_frame": "maximum up to 46 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101866"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Biota Scientific Management Pty Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biota Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}